A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Zetomipzomib (Primary) ; Mycophenolate mofetil; Prednisolone
- Indications Lupus nephritis; Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Acronyms MISSION
- Sponsors Kezar Life Sciences
- 13 Nov 2023 According to Kezar media release, an encore poster presentation of the results at the upcoming 25th Asia-Pacific League of Associations for Rheumatology (APLAR) Congress, which is taking place December 7 - 11, 2023, in Thailand.
- 10 Aug 2023 According to Kezar media release, The post-hoc analysis of MISSION Phase 2 patients with nephrotic range proteinuria and the unmet need of European patients with LN were presented as oral presentations at the 60th European Renal Association (ERA) Congress, which took place June 15-18, 2023 in Milan, Italy.
- 10 Aug 2023 According to Kezar media release, The complete MISSION Phase 2 results, MISSION Phase 2 uCD163 data, and the unmet need of European patients with LN were presented as poster presentations at the European Alliance of Associations for Rheumatology (EULAR) 2023 Congress, which took place May 31 - June 3, 2023 in Milan, Italy